By gdpawel at 2008-09-12 04:09
Antivascular activity of lapatinib and bevacizumabtermterm in primary microcluster cultures of breast cancer and other human neoplasms
Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other
Meeting: 2008 Breast Cancer Symposium
Abstract No: 166
Author(s): L. Weisenthal, D. J. Lee, N. Patel
The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinibterm (Su), sorafenibterm (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).
read more | 1 comment | 4269 reads